Granules India has received its board’s nod to raise Rs 250 crore by issue of equity shares to qualified institutional buyers (QIB). The company’s board also approved sub-division of the face value of the company’s equity shares from Rs 10 each to Re 1 each.
The company’s net profit increased 8 per cent at Rs 23.6 crore in the third quarter ended December 31, 2014 compared to Rs 22 crore in the year-ago period. The revenue of the Hyderabad-based company increased 13 per cent at Rs 320 crore (Rs 284 crore) in the same period.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: